Miraculins closes $400,000 private placement:
This article was originally published in Clinica
Canadian cancer biomarker specialist Miraculins has raised $428,000 from the private placement of approximately 1.2 million units of company stock at a price of $0.35 per unit. Each unit comprised of one common share and half a share purchase warrant. One whole warrant enables the holder to purchase a Miraculins share at $0.65 per share for the twelve-month period after the issuing of the unit. Winnipeg, Manitoba-based Miraculins said the proceeds would be used for R&D and working capital purposes. The company's main focus is on biomarker discovery using its BEST Platform, for screening and identifying target proteins and peptides related to diseases.